Ovarian Cancer  >>  pegylated liposomal doxorubicin  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegylated liposomal doxorubicin / Generic mfg.
NCT00743431: Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)

Completed
N/A
224
Europe
Caelyx (Pegylated Lyposomal Doxorubicin)
Merck Sharp & Dohme LLC
Ovarian Neoplasms
12/08
12/08
NCT00746694: A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)

Completed
N/A
154
Europe
Merck Sharp & Dohme LLC
Ovarian Neoplasms, Breast Neoplasms, Paresthesia
06/09
06/09
NCT00720096: Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

Terminated
N/A
4
US
Liposomal Doxorubicin, Doxil, Topotecan, Hycamtin
H. Lee Moffitt Cancer Center and Research Institute, United States Department of Defense
Ovarian Cancer
10/09
10/09

Download Options